Back to Search
Start Over
Pulmonary manifestations, treatments and outcomes of IgG4-related disease-a systematic literature review.
- Source :
-
Rheumatology international [Rheumatol Int] 2024 Oct; Vol. 44 (10), pp. 1875-1886. Date of Electronic Publication: 2024 May 20. - Publication Year :
- 2024
-
Abstract
- Immunoglobulin G4-related disease (IgG4-RD) is a multisystem fibroinflammatory condition. A consistent feature of many cases is pulmonary infiltrates, or respiratory failure. This systematic literature review aims to summarise the pulmonary manifestations of IgG4-RD, including clinical outcomes and treatment. This review was registered on PROSPERO (CRD42023416410). Medline, Embase and Cochrane databases were searched for articles discussing IgG4-RD syndrome. Information was extracted on demographics, type and prevalence of pulmonary manifestations, treatment and clinical outcomes. Initially, after deduplication, 3123 articles were retrieved with 18 ultimately included. A pooled total of 724 patients with IgG4-RD were included, 68.6% male, mean age 59.4 years (SD 5.8) at disease onset. The most frequently described pulmonary manifestation was mediastinal lymphadenopathy (n = 186, 48.8%), followed by pulmonary nodules (n = 151, 39.6%) and broncho-vascular thickening (n = 85, 22.3%). Where treatment was reported, the majority of patients received glucocorticoids (n = 211, 93.4%). Other immunosuppressive therapy included cyclophosphamide (n = 31), azathioprine (n = 18), with mycophenolate mofetil (n = 6), rituximab (n = 6), methotrexate (n = 5) and other unspecified immunomodulators (50). Clinical outcomes were reported in 263 patients, where 196 patients had remission of their disease, 20 had relapse, 35 had stable disease, four had progression and eight patients died from complications of IgG4-RD. This systematic review summarises pulmonary manifestations, treatments and outcomes in patients with IgG4-RD. Pulmonary involvement in IgG4-RD is relatively common, leading to high levels of morbidity and mortality. Glucocorticoids remain the mainstay of treatment, but further work is required to explore the management of patients with pulmonary manifestations in association with IgG4-RD.<br /> (© 2024. The Author(s).)
- Subjects :
- Female
Humans
Male
Middle Aged
Glucocorticoids therapeutic use
Immunoglobulin G blood
Lymphadenopathy diagnosis
Lymphadenopathy drug therapy
Lymphadenopathy immunology
Treatment Outcome
Immunoglobulin G4-Related Disease complications
Immunoglobulin G4-Related Disease diagnosis
Immunoglobulin G4-Related Disease drug therapy
Immunoglobulin G4-Related Disease immunology
Immunosuppressive Agents therapeutic use
Lung Diseases diagnosis
Lung Diseases drug therapy
Lung Diseases immunology
Subjects
Details
- Language :
- English
- ISSN :
- 1437-160X
- Volume :
- 44
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Rheumatology international
- Publication Type :
- Academic Journal
- Accession number :
- 38769126
- Full Text :
- https://doi.org/10.1007/s00296-024-05611-7